Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives

Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives

Carcinosarcomas (CS) in gynecology are very infrequent and represent only 2–5% of uterine cancers. Despite surgical cytoreduction and subsequent chemotherapy being the primary treatment for uterine CS, the overall five-year survival rate is 30 ± 9% and recurrence is extremely common (50–80%). Due to...

Full description

Bibliographic Details
Main Authors: Salvatore Giovanni Vitale, Antonio Simone Laganà, Stella Capriglione, Roberto Angioli, Valentina Lucia La Rosa, Salvatore Lopez, Gaetano Valenti, Fabrizio Sapia, Giuseppe Sarpietro, Salvatore Butticè, Carmelo Tuscano, Daniele Fanale, Alessandro Tropea, Diego Rossetti
Format: Article
Language:English
Published: MDPI AG 2017-05-01
Series:International Journal of Molecular Sciences
Subjects:
carcinosarcomas
uterine cancer
genetics
epigenetics
immunotherapy
Online Access:http://www.mdpi.com/1422-0067/18/5/1100

Similar Items

Similar Items